Skip to main content
Fig. 3 | BMC Veterinary Research

Fig. 3

From: Cytoplasmic glycoengineering of Apx toxin fragments in the development of Actinobacillus pleuropneumoniae glycoconjugate vaccines

Fig. 3

Glycosylation of ApxIAD3 (Ca2+-binding domain). a- Schematic representation of ApxIAD3. The peptide sequence was engineered to include N- and C-terminal NAT sequons as well as three separate internal modifications. The three ApxIAD3 variants were expressed in E. coli with and without chromosomally encoded ngt and agt. The fragments were purified by Ni-NTA affinity chromatography, resolved by SDS-PAGE and detected by either coomassie stain (b) or the presence of glycoprotein detected by PAS staining (c)

Back to article page